logo
Book a meeting
Spexis AG

Spexis Ag

Pharmaceuticals, 197 W Springfield St, Allschwil, Massachusetts, 02118, United States, 11-50 Employees

spexisbio.com

  • twitter
  • LinkedIn

phone no Phone Number: +41*********

Who is SPEXIS AG

Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options are u...

Read More

lock icon Get Full Access
map
  • 197 W Springfield St, Allschwil, Massachusetts, 02118, United States Headquarters: 197 W Springfield St, Allschwil, Massachusetts, 02118, United States
  • 1996 Date Founded: 1996
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Pharmaceuticals

SIC SIC Code: 2834

checked-icon Does something look wrong? Fix it. | View contact records from SPEXIS AG

Spexis AG Org Chart and Mapping

Employees
Theo Scheurmann

Theo Scheurmann

Head of Information Technology

See Full Org Chart arrow
email-formate-icon
View Email Formats for Spexis AG
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding Spexis AG

Answer: Spexis AG's headquarters are located at 197 W Springfield St, Allschwil, Massachusetts, 02118, United States

Answer: Spexis AG's phone number is +41*********

Answer: Spexis AG's official website is https://spexisbio.com

Answer: Spexis AG's revenue is $1 Million to $5 Million

Answer: Spexis AG's SIC: 2834

Answer: Spexis AG has 11-50 employees

Answer: Spexis AG is in Pharmaceuticals

Answer: Spexis AG contact info: Phone number: +41********* Website: https://spexisbio.com

Answer: Spexis AG (SIX:SPEX) is a publicly-listed Swiss clinical-stage biopharmaceutical company developing rare disease and oncology treatments in indications where new therapeutic options are urgently needed. Spexis AG was launched in December 2021 by the reverse merger of EnBiotix, Inc. (Boston, MA, USA) and Polyphor AG (Allschwil, Switzerland), with EnBiotix shareholders resulting in the majority. Our focus is on chronic respiratory diseases (CRD), and our lead product candidate ColiFin is P3 ready. ColiFin is an inhaled colistimethate sodium product in-licensed from PARI Pharma GmbH for ex-European rights. Approved and marketed in Europe as a front-line therapy in cystic fibrosis (CF) patients, ColiFin already has a proven safety, efficacy, and commercial track record. In the U.S., ColiFin has Orphan Drug and Qualified Infectious Disease Product (QIDP) designations, which together will provide a total of 12 years of market exclusivity from NDA approval. We also have a Study May Proceed letter from the FDA regarding a single phase 3 study evaluating ColiFin in CF patients being sufficient to support a future New Drug Application (NDA). The trial design has been endorsed by the Cystic Fibrosis Foundation (CFF) Therapeutic Development Network (TDN), the clinical development arm of the CFF. Of note, the CFF also invested in the pre-merger financing launching Spexis.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access